Conference Call with Dr. Lal Pathlabs Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services company Dr. Lal Pathlabs announced Q4FY23 & FY23 results: Dr. Lal PathLabs records revenue of Rs 491 crore in Q4FY23 Non-Covid Revenue increased by 14.4% in Q4FY23 & 15.5% in FY23 Normalised EBITDA margin (after adjustment for stock-based compensation, CSR & exceptional expenses) for Q4FY23 is 26.6% & 26.2% for FY23 The normalised PAT margin for Q4FY23 is 15.5% and 14.7% for FY23 Result PDF